Drugs that target KRAS 12C covalently, AMG 510 and MRTX849, are now in the clinic. Recent papers describe development of these compounds, their selectivity and properties, early clinical data, and potential combination therapies. These papers herald a new era in Ras research, with improved drugs and strategies certain to follow.

中文翻译：

---

坚持使用KRAS：共价抑制剂进入诊所。

目前，可共价靶向KRAS 12C的药物AMG 510和MRTX849。最近的论文描述了这些化合物的开发，其选择性和性质，早期临床数据以及潜在的联合疗法。这些论文预示着Ras研究的新纪元，随之而来的是改进的药物和策略。